1600 Participants Needed

Gene Mutation Identification for Pancreatic Cancer

Recruiting at 26 trial locations
YY
Overseen ByYing Yuan, PHD
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to collect samples such as blood, saliva, urine, or stool from children to identify genetic mutations that may increase the risk of pancreatic cancer. The focus is on children who have experienced acute recurrent pancreatitis (sudden inflammation of the pancreas) or chronic pancreatitis (long-term inflammation of the pancreas). Participants must have had conditions like repeated episodes of acute pancreatitis or irreversible changes in their pancreas that persist over time. Children involved will also complete questionnaires and quality-of-life assessments annually for four years. This research seeks to find genetic markers that can help identify those at risk of developing pancreatic cancer. As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research that could lead to early detection and prevention strategies for pancreatic cancer in children.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinator or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover specific gene mutations linked to high-risk pancreatic cancer in children. Unlike traditional treatment approaches that focus on managing symptoms or targeting the cancer directly, this study focuses on collecting biospecimens like blood, saliva, urine, and stool to identify genetic markers. By pinpointing these mutations, the study could pave the way for more personalized and effective treatments in the future. This approach represents a shift towards precision medicine, where understanding the genetic underpinnings of the disease could lead to earlier detection and tailored interventions, potentially improving outcomes for young patients.

Who Is on the Research Team?

YY

Ying Yuan, PHD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I experience abdominal pain consistent with acute pancreatitis.
I have signed the informed consent for this study.
I have signed a form allowing my or my child's health information to be shared.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline

Collection of blood, saliva, urine, or stool samples and completion of quality-of-life assessment and questionnaires

1 day
1 visit (in-person)

Follow-up

Participants complete quality-of-life assessment and questionnaires every 12 months for 4 years, with additional biospecimen collection if needed

4 years
Annual visits (in-person)

Long-term follow-up

Participants are followed up every 12 months after completion of the study

Indefinite

What Are the Treatments Tested in This Trial?

Interventions

  • Biospecimen Collection

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Observational (biospecimen collection and questionnaire)Experimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+